APA (7th ed.) Citation

C, X., C, W., Y, Z., W, Y., Y, Z., Y, G., . . . L, Z. (2026). Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance. Annals of hematology, 105(7), . https://doi.org/10.1007/s00277-026-07028-7

Chicago Style (17th ed.) Citation

C, Xue, et al. "Short-term Blinatumomab for B-cell Acute Lymphoblastic Leukemia Pediatric Patients Results in Measurable Residual Disease Clearance." Annals of Hematology 105, no. 7 (2026). https://doi.org/10.1007/s00277-026-07028-7.

MLA (9th ed.) Citation

C, Xue, et al. "Short-term Blinatumomab for B-cell Acute Lymphoblastic Leukemia Pediatric Patients Results in Measurable Residual Disease Clearance." Annals of Hematology, vol. 105, no. 7, 2026, https://doi.org/10.1007/s00277-026-07028-7.